Jubilant Pharmova successfully concluded its 48th Annual General Meeting, with shareholders approving a dividend of Rs 5 per equity share. The company reported a 14% growth in FY26 revenue to Rs 8,300 crore and a 17% growth in Q1 FY27 revenue. While the CDMO and radiopharmaceuticals segments show strong long-term growth, recent profitability was impacted by temporary supply constraints and facility remediation costs. Investors are advised to watch for margin recovery in the coming quarters as production stabilizes and new manufacturing lines ramp up.
Jubilant Pharmova 48th AGM Outcome and Financial Review
FY26 Consolidated Revenue: Rs 8,300 crore; Normalised PAT: Rs 400 crore.
Reader Takeaway: Strong growth in CDMO and Generics offset by temporary margin pressure from facility remediation and supply issues.
What just happened
Jubilant Pharmova held its 48th Annual General Meeting (AGM) on August 26, 2026, where shareholders approved all proposed resolutions. A final dividend of Rs 5 per equity share was declared. The meeting also saw the reappointment of Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia as directors.
Why this matters
Beyond the dividend, the AGM provided a window into the company's operational health. While FY26 results were strong—with a 14% rise in revenue—the Q1 FY27 numbers show early signs of margin pressure. Revenue grew 17% year-on-year to Rs 2,200 crore, but EBITDA reached Rs 270 crore due to production bottlenecks at the Montreal facility and the temporary unavailability of high-margin radiopharmaceuticals.
Operational Performance
- CDMO Sterile Injectables: Revenue grew 38% in FY26, supported by the launch of Line 3 at the Spokane facility.
- Radiopharmaceuticals: Achieved a robust 41% EBITDA margin in FY26, with a new distribution partnership for Pluvicto®.
- Generics: EBITDA surged 250% following a 13% rise in revenue, highlighting a significant improvement in unit profitability.
Risks to watch
The primary concern remains the company's margin trajectory in H2 FY27. Management is focused on normalizing production at the Montreal site and completing construction on the new Line 5 facility. Additionally, the Net Debt-to-EBITDA ratio has shifted from 1.1x to 1.3x, driven by aggressive capital expenditure to support Vision 2030, which investors should monitor closely as these projects mature.
What to track next
Shareholders should look for updates regarding the resolution of supply constraints in the SPECT business and the successful onboarding of global oncology products to the Spokane and Montreal manufacturing lines.